Satellos Bioscience Inc. MSLE Stock Forecast
AI-powered price prediction and analysis for Satellos Bioscience Inc. · Total · absolute moveSwitch to Alpha
See MSLE's Exact Price Target · Create a free account and follow this stock to unlock its full AI forecast — 3 stocks free.
Price Chart
Key Statistics
About Satellos Bioscience Inc.
Satellos Bioscience Inc. (MSLE) operates within the Life Sciences sector, specifically in the Pharmaceutical Preparations industry.
Latest News
Where MSLE sits on the market map
Pharmaceutical Preparations Peers
Companies sharing the same SEC industry code, one row per issuer, largest first - a classification match, not a curated list of competitors.
| Company | AI Signal | Market Cap | P/E |
|---|---|---|---|
| MSLE Satellos Bioscience Inc. | ▶ | $109M | – |
| LLY Eli Lilly & Co | ▶ | $1.14T | 42.6x |
| JNJ Johnson & Johnson | ▼ | $611.90B | 29.1x |
| ONC Beone Medicines Ltd. | ▶ | $519.53B | – |
| ABBV Abbvie Inc. | ▼ | $501.24B | 79.4x |
| MRK Merck & Co., Inc. | ▼ | $363.59B | 114.6x |
| NVS Novartis Ag | ▼ | $280.27B | – |
| GSK Gsk Plc | ▼ | $206.58B | – |
| ABT Abbott Laboratories | ▼ | $179.37B | 28.6x |
| PFE Pfizer Inc | ▶ | $166.49B | 38.4x |
| VRTX Vertex Pharmaceuticals Inc / … | ▼ | $126.35B | 28.7x |
| BMY Bristol Myers Squibb Co | ▼ | $121.09B | 13.1x |
| REGN Regeneron Pharmaceuticals, Inc. | ▼ | $80.14B | 18.5x |
| SNY Sanofi | ▼ | $48.50B | – |
| TEVA Teva Pharmaceutical Industries Ltd | ▶ | $47.45B | 67.1x |
| RPRX Royalty Pharma Plc | ▶ | $33.92B | 41.6x |
| ZTS Zoetis Inc. | ▼ | $31.11B | 11.9x |
| TAK Takeda Pharmaceutical Co Ltd | ▼ | $30.24B | – |
| ALNY Alnylam Pharmaceuticals, Inc. | ▼ | $30.04B | – |
| ATHE Alterity Therapeutics Ltd | ▶ | $25.65B | – |
| ZLAB Zai Lab Ltd | ▼ | $25.26B | – |
| ROIV Roivant Sciences Ltd. | ▶ | $24.28B | – |
| UTHR United Therapeutics Corp | ▼ | $23.16B | 17.7x |
| INSM Insmed Inc | ▼ | $21.36B | – |
| VTRS Viatris Inc | ▶ | $20.03B | – |
| ASND Ascendis Pharma A/S | ▶ | $14.07B | – |
| JAZZ Jazz Pharmaceuticals Plc | ▼ | $13.61B | 14.5x |
| BBIO Bridgebio Pharma, Inc. | ▶ | $12.69B | – |
| CORT Corcept Therapeutics Inc | ▲ | $12.56B | – |
| KNSA Kiniksa Pharmaceuticals International, Plc | ▲ | $12.30B | – |
| SMMT Summit Therapeutics Inc. | ▶ | $12.07B | – |
| HCM Hutchmed (China) Ltd | ▶ | $11.76B | – |
| ELAN Elanco Animal Health Inc | ▲ | $11.27B | – |
| BMRN Biomarin Pharmaceutical Inc | ▼ | $10.67B | – |
| RDY Dr Reddys Laboratories Ltd | ▼ | $10.64B | – |
| MDGL Madrigal Pharmaceuticals, Inc. | ▶ | $10.63B | – |
| PTGX Protagonist Therapeutics, Inc | ▲ | $8.82B | – |
| CYTK Cytokinetics Inc | ▶ | $8.82B | – |
| AXSM Axsome Therapeutics, Inc. | ▼ | $8.50B | – |
| ARWR Arrowhead Pharmaceuticals, Inc. | ▲ | $8.25B | – |
| IONS Ionis Pharmaceuticals Inc | ▶ | $7.10B | – |
| LEGN Legend Biotech Corp | ▶ | $7.04B | – |
| SYRE Spyre Therapeutics, Inc. | ▲ | $6.93B | – |
| ABVX Abivax S.A. | ▼ | $6.91B | – |
| PRAX Praxis Precision Medicines, Inc. | ▶ | $6.67B | – |
| ALKS Alkermes Plc. | ▶ | $6.56B | – |
| AMRX Amneal Pharmaceuticals, Inc. | ▶ | $6.04B | – |
| BLTE Belite Bio, Inc | ▲ | $6.01B | – |
| RYTM Rhythm Pharmaceuticals, Inc. | ▶ | $5.97B | – |
| LGND Ligand Pharmaceuticals Inc | ▼ | $5.88B | 29.8x |
| BLRX Biolinerx Ltd. | ▼ | $5.43B | – |
| MIRM Mirum Pharmaceuticals, Inc. | ▲ | $5.19B | – |
| ERAS Erasca, Inc. | ▲ | $5.14B | – |
| TVTX Travere Therapeutics, Inc. | ▲ | $5.02B | – |
| PTCT Ptc Therapeutics, Inc. | ▶ | $4.98B | – |
| COGT Cogent Biosciences, Inc. | ▲ | $4.88B | – |
| AMRN Amarin Corp Plc\Uk | ▶ | $4.88B | – |
| MANE Veradermics, Inc | ▲ | $4.74B | – |
| GPCR Structure Therapeutics Inc. | ▲ | $4.68B | – |
| DNTH Dianthus Therapeutics, Inc. /De/ | ▲ | $4.18B | – |
FAQ
Is Satellos Bioscience Inc. a good stock to buy?
Our AI analyzes Satellos Bioscience Inc. daily. Check the signal above for the latest recommendation. Always do your own research before investing.
How accurate are Satellos Bioscience Inc. predictions?
A per-ticker accuracy statistic for MSLE is published only once its sample size is known. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are forecasts updated?
Satellos Bioscience Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 14, 2026.
Ready to invest smarter? · Join thousands of investors using AI-powered stock predictions
Sign Up FreeLooking for a deeper analysis of Satellos Bioscience Inc.? View full institutional-grade analysis on Intratio →
AI predictions are based on historical patterns and should not be the sole basis for investment decisions. Past performance does not guarantee future results. Always do your own research.